Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by blackascanbeon May 26, 2010 12:18pm
500 Views
Post# 17132503

let's not forget brad galer's resume as well

let's not forget brad galer's resume as wellBoard of Directors

Daniel N. Chicoine, CA - Chairman & Co-Chief Executive Officer
Since 1982, Mr. Chicoine has held various positions at the Magna group of companies, including President and CEO of Atoma International Inc. While Mr. Chicoine was the CEO of Atoma, he succeeded in growing its business from $300 million per annum to $1 billion and effected a major restructuring. In May 1994, Mr. Chicoine formed Triam Automotive Inc., an automobile parts supplier, with other former executives of Magna and, in July 1994, was instrumental in assisting the company in completing an initial public offering. While at Triam, he acted as Vice Chairman in charge of sales. After leaving Triam in 1996, Mr. Chicoine, along with two other former executives of Magna, formed Nighthawk Investments, a small investment company. Mr. Chicoine has also served as the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. Mr. Chicoine is a chartered accountant by profession.

David A. Copeland, CA - Chair of the Audit Committee, Lead Director
Mr. Copeland was the former President and Chief Operating Officer, Triam Automotive Inc., an automobile parts supplier. Prior to Triam, Mr. Copeland was Chief Financial Officer of Magna International Inc. and President and Chief Operating Officer of the Cosma Group of Magna. He is currently an active investor in early stage companies. His background includes practicing as a chartered accountant and a focus on business valuation and mergers and acquisitions.

Anthony E. Dobranowski, CA, MBA
Private Business Consultant. Mr. Dobranowski retired from Magna International Inc., a global automotive parts supplier, in 2007. During his employment with Magna, Mr. Dobranowski was most recently a Vice President of Magna, and prior to that held various executive positions (Vice Chairman, President and CFO) at Tesma International Inc., a publicly traded Magna subsidiary. He was instrumental in the initial public offering of Tesma in 1995, and was involved in all aspects of Tesma's growth, with particular emphasis on financing, investor relations and M&A activity. Previous to that, Mr. Dobranowski held various senior management positions with other Magna companies. Mr. Dobranowski holds an MBA from the University of Toronto and is also a chartered accountant.

Dr. Henrich R.K. Guntermann, MD, MSc - President, Europe & Immunology Group
President and CEO, Nuvo Research Inc. Dr. Guntermann has more than 15 years of experience in the life sciences sector (including business development, restructuring and corporate financing). With a group of distinguished life sciences entrepreneurs, he founded BioAlliance AG, a German-based life sciences private equity and consulting firm. BioAlliance was formed to capitalize on the early stage development of the life sciences industry in the European Union, by developing life sciences companies and leveraging their technologies and products worldwide. Through its established international network, it brings together life sciences companies in the United States, Asia and Europe to foster growth through alliances. In addition, BioAlliance consults for international life sciences companies (pharmaceutical, medical devices, diagnostics and agro-biotech) in different stages of development, including large scale players in the life sciences sector and public institutions, such as city and state governments, the European Commission and the United Nations Industry Development Organization (UNIDO). Dr. Guntermann received his medical doctorate at the Philipps-University in Marburg, Germany. He also received a Masters of Science in Biology, with specialization in pharmacology/toxicology and human genetics.

Dr. Klaus von Lindeiner, Dr en droit
Private business consultant. Prior to his retirement in 2000, Mr. von Lindeiner served as a senior executive for various European multinationals, including Wacker-Chemie GmbH, Lurgi GmbH and Metallgesellschaft AG. Previously, Mr. von Lindeiner worked as a legal advisor to the United Nations, Office of the High Commissioner for Refugees, as well as in the Organizational Committee for the 1972 Munich Olympic Games. He has served as a member of the regional advisory boards of Deutsche Bank AG, Allianz Insurance AG, and Dresdner Bank AG. He has also served as a director on the boards of GEFIU, Power Paper Ltd. and OXO Chemie AG. Currently, Mr. von Lindeiner serves as a member of the Supervisory Board of Bayerische Landesbank and the Advisory Board of Golding Capital Partners. Mr. von Lindeiner has a professional legal background with a doctorate in international law from the University of Geneva/Switzerland.

John C. London, LLB, LLM - President & Co-Chief Executive Officer
Mr. London is a graduate of the University of Western Ontario law school and holds a Masters of Law Degree from University College London. He was a partner with the Toronto law firm of Strathy, Archibald and Seagram (now Gowlings) where he practiced from 1981 to 1988. In 1988, Mr. London joined Magna International Inc., one of the world's largest automotive parts suppliers. From 1988 to 1993, he was Executive Vice-President and General Counsel at Atoma International Inc., Magna's interior systems group. In 1994, Mr. London co-founded Triam Automotive Inc., a private auto parts supplier, where he served as Executive Vice-President. Mr. London and his partners took Triam public and sold it to Magna in 1998. In 1997 Mr. London co-founded Nighthawk Investments, a private investment firm. From 2002 to 2005, Mr. London was President and Chief Executive Officer of Powercart Systems Inc. a private company that designs and manufactures battery equipped workstations that power devices with wireless communication capability.

Dr. Jacques Messier, DVM, MBA - Chair of the Compensation and Corporate Governance Committee
Director of the Veterinary Teaching Hospital at the University of Saskatchewan. Most recently Dr. Messier was the Chief Executive Officer, The Semex Alliance, a partnership specializing in the development and marketing of high quality genetic technologies, products and services to benefit livestock producers around the world. Previously, Dr. Messier was involved in management consulting in a number of specialized assignments pulling from his experience from many different business sectors. From 1995 to 2001 Dr. Messier held various positions at Novopharm Ltd. a generic pharmaceutical company, including President and Chief Executive Officer. Dr. Messier was Chief Operating Officer of publicly-traded KV Pharmaceutical Company from 2001 to 2003. Dr. Messier has also held a variety of management positions with Agriculture Canada and Health Welfare, including the Director of the Bureau of Human Prescription Drugs. He started his career as a Doctor of Veterinary Medicine, and practiced large animal medicine at his veterinary clinic in Saskatchewan for six years before joining Agriculture Canada. Dr. Messier also holds an MBA from the University of Western Ontario.
Bullboard Posts